Contract development and manufacturing organisation (CDMO) PharmaLogic is set to acquire a majority stake in Agilera Pharma to generate the first fully integrated, worldwide CDMO focusing on radiopharmaceutical therapies.
The acquisition will enhance PharmaLogic’s current therapeutic manufacturing platform, enabling the company to offer radiopharmaceutical solutions globally.
Go deeper with GlobalData
PharmaLogic aims to invest in Agilera’s CDMO offerings expansion, bolstering its infrastructure, and scale its manufacturing footprint to meet the growing worldwide demand for these therapeutics.
Through this move, PharmaLogic will produce and distribute to pharmaceutical companies one of the prime radiopharmaceutical therapies that are commercially approved.
The acquisition closure is expected in June 2025, contingent on customary conditions, including the transfer of licence, regulatory approvals and specific third-party consents.
Solomon Partners Securities was the financial advisor for the acquisition.
PharmaLogic president Etienne Montagut stated: “PharmaLogic’s acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field.
“By combining our expertise with Agilera’s industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments.”
Agilera Pharma, established as a subsidiary of Norway’s Institute for Energy Technology (IFE) in 2023, currently employs 140 people. It claims to have delivered more than 600,000 commercial therapeutic doses to over 40 nations.
Agilera Pharma CEO Erik Flatmark stated: “With PharmaLogic as a new owner beside IFE, this will enable further investments in the business to ensure that we have the right, available capacity to take on new customer projects and thus achieve faster adaptation to the promising market opportunities.”
In May 2023, NUCLIDIUM signed a strategic partnership deal with PharmaLogic for the manufacture and clinical supply of copper-based theranostics ⁶¹Cu in the US.
